April 2022

According to the recent Study of Mirtazapine for Agitated Behaviors in Dementia (SYMBAD) trial, there was no improvement in agitation in patients with Alzheimer disease taking mirtazapine compared with placebo. Furthermore, the treatment group had more deaths than the placebo group, and the investigators suggested that mirtazapine should no longer be used for agitation in patients with dementia.
Read More

Results of a recent study show that antidepressant prescription fills during pregnancy were associated with a small decrease in standardized test scores in children for mathematics but not for language.
Read More

Brivaracetam as adjunctive therapy for focal seizures is safe, well-tolerated, and efficacious, according to the results of a long-term follow-up study of participants in earlier clinical trials.
Read More

A recent open-label study found that improvements in migraine frequency and severity with erenumab for episodic migraines were durable and not associated with any new safety concerns.
Read More

Patients with multiple sclerosis who were recently treated with anti-CD20 monoclonal antibody therapies had reduced antibody and B-cell responses but intact T-cell responses to SARS-CoV-2 mRNA vaccination compared with healthy people.
Read More

Subscribe to
Value-Based Care in Neurology

Stay up to date with personalized medicine by subscribing to receive the free VBCN e‑Newsletter.

I'd like to receive: